Table 2. Genotype-specific parameters including treatment efficacy, duration and safety.
| Indication [Source] | SOF-based and comparator strategies | SVR | Discontinued# | Patients with adverse events | |||
|---|---|---|---|---|---|---|---|
| cirrhotic | Non-cirrhotic | Due to AEs | Other reasons | Any | Serious | ||
| GT1 TN IE [13,32,33] | SOF + PegIFN2a + RBV for 12 wks | 80.8% | 91.3% | 1.7% at 5.3 wks | 0.7% at 4.8 wks | 95% | 1% |
| PegIFN2a/2b + RBV for 48 wks | 23.6% | 43.6% | 7.0% at 24 wks | 24% at 24 wks | 96% | 1% | |
| TEL + PegIFN2a + RBV for 24/48 wks | 61.9% | 75.4% | NA | 23.3% at 18 wks | 100% | 21% | |
| BOC + PegIFN2b + RBV for 28/48 wks | 55.0% | 64.1% | NA | 26.1% at 24 wks | 99% | 13% | |
| GT1 TN II [34] | SOF + RBV for 24 wks | 53.3% | 68.3% | 1% at 12 wks | 0% | 89% | 0% |
| NT | 0% | 0% | 0% | 0% | 69% | 0% | |
| GT2 TN IE [13]* | SOF + RBV for 12 wks | 90.9% | 98.3% | 0% | 0% | 86% | 3% |
| PegIFN2a/2b + RBV for 24 wks | 61.5% | 81.5% | 12% at 14.9 wks | 6 | 96% | 1% | |
| GT2 TN II [12] | SOF + RBV for 12 wks | 93.3% | 91.8% | 1% at 0.9 wks | 1% at 1.3 wks | 89% | 5% |
| NT | 0% | 0% | 0% | 0% | 78% | 0% | |
| GT3 TN IE [13,16,35,36] | SOF + RBV for 24 wks | 92.3% | 93.5% | 0.4% at 21.5 wks | 1.2% at 21.5 wks | 92% | 4% |
| SOF + PegIFN2a + RBV for 12 wks | 83.3% | 100% | 0% | 0% | NA | 1% | |
| PegIFN2a/2b + RBV for 24 wks | 29.7% | 71.2% | 10.2% at 10.8 wks | 13.6% at 11.9 wks | 96% | 1% | |
| GT3 TN II [35] | SOF + RBV for 24 wks | 92.3% | 93.5% | 0.4% at 21.5 wks | 1.2% at 21.5 wks | 92% | 4% |
| NT | 0% | 0% | 0% | 0% | 71% | 0% | |
| GT3 TE IE [16,35,37,38] | SOF + RBV for 24 wks | 62% | 87% | 0.4% at 21.5 wks | 1.2% at 21.5 wks | 92% | 4% |
| SOF + PegIFN2a + RBV for 12 wks | 83.3% | 83.3% | 8% at 1 wk | 0% | 96% | 1% | |
| PegIFN2a/2b + RBV for 48 wks | 35% | 35% | 36.8% at 24 wks | 0% | 100% | 1% | |
| GT3 TE II [35] | SOF + RBV for 24 wks | 60% | 85% | 0.4% at 21.5 wks | 1.2% at 21.5 wks | 92% | 4% |
| NT | 0% | 0% | 0% | 0% | 71% | 0% | |
| GT4 TN [13,39] | SOF + PegIFN2a + RBV for 12 wks | 50% | 100% | 0% | 0% | 95% | 2% |
| PegIFN2a/2b + RBV for 48 wks | 38.6% | 50% | 14% at 24 wks | 26% at 24 wks | 96% | 1% | |
BOC, boceprevir; GT, genotype; IE, interferon eligible; II, interferon ineligible; NA, not available; PegIFN, pegylated interferon; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response; TE, treatment-experienced; TEL, telaprevir; TN, treatment-naïve
* head-to-head comparison trial
# the percentages of patients and the time point at which these patients have discontinued treatment due to adverse events or other reasons before the end of the planned treatment duration